How should cholestatic pruritus associated with chronic hepatitis C or its antiviral therapy be managed?

Management of Cholestatic Pruritus in Hepatitis C

For cholestatic pruritus associated with chronic hepatitis C or its antiviral therapy, rifampicin should be your first-line treatment at 150 mg daily, titrating up to 600 mg daily as needed, with monitoring of liver function tests. This represents a shift from older recommendations, as the most recent high-quality evidence demonstrates superior efficacy for rifampicin over traditional bile acid sequestrants 1.

Treatment Algorithm

First-Line: Rifampicin

• Start with rifampicin 150 mg twice daily (can begin at 150 mg once daily if concerned about tolerability)
• Increase stepwise to maximum 600 mg twice daily if needed 1
• Monitor serum liver tests regularly for hepatotoxicity 2
• Warn patients about orange discoloration of secretions (tears, urine, sweat) 1
• Meta-analyses show rifampicin reduces hepatic pruritus without increased side effects compared to placebo 1

Second-Line: Cholestyramine

If rifampicin fails or is not tolerated:

• Cholestyramine 4 g up to four times daily 2
• Must be spaced at least 4 hours away from other medications to prevent binding 2
• Monitor fat-soluble vitamins (A, D, E, K) during long-term use 2
• Evidence is limited with heterogeneous trial data, but it remains guideline-recommended 1

Third-Line: Sertraline

• Sertraline 75-100 mg daily 1, 3
• Well-tolerated with good efficacy in controlled trials 3
• Works through serotonergic pathways involved in itch perception 3
• Should be used before opioid antagonists due to better side effect profile 1

Fourth-Line: Naltrexone

• Naltrexone 50 mg daily, starting at 25 mg 2
• Significantly more side effects than rifampicin or cholestyramine 1
• Alternative opioid antagonists include nalmefene or methylnaltrexone 1

Fifth-Line Options

Consider for refractory cases:

• Systemic dronabinol, phenobarbitone, or topical tacrolimus 1
• Novel agents targeting bile acid transport, autotaxin, or lysophosphatidic acid pathways 1
• Phototherapy (BB-UVB or combined UVA/UVB) 1

Important Considerations

Guideline Discrepancy

There is a notable divergence between guidelines. The 2009 EASL cholestatic liver disease guidelines 2 recommend cholestyramine first-line, while the 2018 British Association of Dermatologists guidelines 1 recommend rifampicin first-line based on stronger meta-analytic evidence. The more recent 2018 guidelines with Level 1+ evidence should take precedence.

Hepatitis C-Specific Context

• Pruritus can occur from the underlying hepatitis C itself or from antiviral therapy 4, 5
• DAA regimens containing ombitasvir/paritaprevir/ritonavir cause pruritus in up to 20% of patients through ritonavir-induced bile acid transport alterations 5
• Treatment-associated pruritus is often self-limiting during therapy 5
• If severe, cholestyramine can be added without interrupting antiviral treatment 5

What NOT to Use

• Do not use gabapentin for hepatic pruritus 1
• Avoid sedating antihistamines long-term (dementia risk); they are ineffective for cholestatic itch anyway 1, 6
• Ondansetron has conflicting evidence and cannot be routinely recommended 1

When to Escalate

• Rule out bile duct obstruction with ultrasound, MRCP, or ERCP before treating medically 2
• Refer to hepatology if significant hepatic impairment is present 1
• Liver transplantation is effective but reserved only for refractory pruritus unresponsive to all medical interventions 2

Practical Pitfalls

• Don't assume antihistamines will work—cholestatic itch is not histamine-mediated 6
• Remember to space cholestyramine away from other medications by 4 hours to maintain their efficacy 2
• Monitor for rifampicin hepatotoxicity, though paradoxically it's used to treat liver disease-related pruritus 2, 1
• Pruritus severity does not correlate with liver disease severity or cholestasis extent 6